| The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report SL Cohn, ADJ Pearson, WB London, T Monclair, PF Ambros, GM Brodeur, ... Journal of clinical oncology 27 (2), 289, 2009 | 2034 | 2009 |
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma AL Yu, AL Gilman, MF Ozkaynak, WB London, SG Kreissman, HX Chen, ... New England Journal of Medicine 363 (14), 1324-1334, 2010 | 1903 | 2010 |
| The international neuroblastoma risk group (INRG) staging system: an INRG task force report T Monclair, GM Brodeur, PF Ambros, HJ Brisse, G Cecchetto, K Holmes, ... Journal of clinical oncology 27 (2), 298, 2009 | 1202 | 2009 |
| The genetic landscape of high-risk neuroblastoma TJ Pugh, O Morozova, EF Attiyeh, S Asgharzadeh, JS Wei, D Auclair, ... Nature genetics 45 (3), 279-284, 2013 | 1196 | 2013 |
| Activating mutations in ALK provide a therapeutic target in neuroblastoma RE George, T Sanda, M Hanna, S Fröhling, WL Ii, J Zhang, Y Ahn, ... Nature 455 (7215), 975-978, 2008 | 1014 | 2008 |
| Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group … KK Matthay, CP Reynolds, RC Seeger, H Shimada, ES Adkins, ... Journal of clinical oncology 27 (7), 1007, 2009 | 983 | 2009 |
| Advances in risk classification and treatment strategies for neuroblastoma NR Pinto, MA Applebaum, SL Volchenboum, KK Matthay, WB London, ... Journal of clinical oncology 33 (27), 3008, 2015 | 822 | 2015 |
| Chromosome 1p and 11q deletions and outcome in neuroblastoma EF Attiyeh, WB London, YP Mossé, Q Wang, C Winter, D Khazi, ... New England Journal of Medicine 353 (21), 2243-2253, 2005 | 733 | 2005 |
| Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group WB London, RP Castleberry, KK Matthay, AT Look, RC Seeger, ... J Clin Oncol 23 (27), 6459-65, 2005 | 682 | 2005 |
| Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease CK Tebbi, WB London, D Friedman, D Villaluna, PA De Alarcon, ... Journal of Clinical Oncology 25 (5), 493-500, 2007 | 525 | 2007 |
| A modified γ-retrovirus vector for X-linked severe combined immunodeficiency S Hacein-Bey-Abina, SY Pai, HB Gaspar, M Armant, CC Berry, S Blanche, ... New England Journal of Medicine 371 (15), 1407-1417, 2014 | 462 | 2014 |
| Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project HJ Brisse, MB McCarville, C Granata, KB Krug, SL Wootton-Gorges, ... Radiology 261 (1), 243-257, 2011 | 462 | 2011 |
| International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee PF Ambros, IM Ambros, GM Brodeur, M Haber, J Khan, A Nakagawara, ... British journal of cancer 100 (9), 1471-1482, 2009 | 460 | 2009 |
| Copy number variation at 1q21. 1 associated with neuroblastoma SJ Diskin, C Hou, JT Glessner, EF Attiyeh, M Laudenslager, K Bosse, ... Nature 459 (7249), 987-991, 2009 | 442 | 2009 |
| ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma SC Bresler, DA Weiser, PJ Huwe, JH Park, K Krytska, H Ryles, ... Cancer cell 26 (5), 682-694, 2014 | 407 | 2014 |
| Clinicopathologic features and long-term outcomes of NUT midline carcinoma DE Bauer, CM Mitchell, KM Strait, CS Lathan, EB Stelow, SC Lüer, ... Clinical cancer research 18 (20), 5773-5779, 2012 | 401 | 2012 |
| Children's Oncology Group's 2013 blueprint for research: neuroblastoma JR Park, R Bagatell, WB London, JM Maris, SL Cohn, KM Mattay, ... Pediatric blood & cancer 60 (6), 985-993, 2013 | 399 | 2013 |
| Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study D Billmire, C Vinocur, F Rescorla, B Cushing, M Schlatter, M Davis, ... Journal of pediatric surgery 39 (3), 424-429, 2004 | 357 | 2004 |
| Outcome after reduced chemotherapy for intermediate-risk neuroblastoma DL Baker, ML Schmidt, SL Cohn, JM Maris, WB London, A Buxton, ... New England Journal of Medicine 363 (14), 1313-1323, 2010 | 346 | 2010 |
| Common variations in BARD1 influence susceptibility to high-risk neuroblastoma M Capasso, M Devoto, C Hou, S Asgharzadeh, JT Glessner, EF Attiyeh, ... Nature genetics 41 (6), 718-723, 2009 | 339 | 2009 |
